Beam Therapeutics Stock
Beam Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- John Evans
- Employees
- 540
- Market cap
- $2.4 B
- IPO
- 06/02/2020
Beam Therapeutics Inc. is a biopharmaceutical company founded in 2017 and headquartered in Cambridge, USA. Operating within the Healthcare sector and the Biotechnology industry, the firm focuses on engineering precise genetic remedies to address a spectrum of severe human ailments, primarily within the United States.…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Beam Therapeutics stock: price history
1D
-5.1%
1W
-8.7%
1M
+1.6%
6M
-25.2%
YTD
-15.3%
1Y
-9.0%
2Y
-12.1%
5Y
-74.8%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~21% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Beam Therapeutics
Analyst assessment of Beam Therapeutics
PRICE TARGET LOW
US$39.00
CONSENSUS
US$59.50
MEDIAN
US$59.50
PRICE TARGET HIGH
US$80.00
0
STRONG BUY
18
BUY
8
HOLD
1
SELL
0
STRONG SELL
27
TOTAL · Buy
As of: 15/10/2026
Beam Therapeutics stock metrics
P/E
-28.62
P/B
2.29
EV/EBITDA
-38.8
RETURN ON EQUITY
-11.5%
NET MARGIN
-25,036.3%
DEBT/EQUITY
0.23
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
85.5%
FLOAT SHARES
88,329,323
AVG. DAILY VOLUME (30D)
1,999,713
Insider transactions (SEC)
Evans John M.
Evans John M.
Evans John M.
Evans John M.
Cavanagh Bethany J
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -5.1%
Forums (Reddit)
Institutional holders
Dividends
Comparable stocks
Frequently asked questions about Beam Therapeutics stock
What does Beam Therapeutics do?
Beam Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is John Evans, the company employs around 540 people.
The IPO was on 06/02/2020; the stock trades on NASDAQ under the ticker BEAM.
What do analysts say about Beam Therapeutics stock?
27 analysts rate the stock, the consensus is Buy (as of 15/10/2026).
The average price target is US$59.50, ranging from US$39.00 to US$80.00, with a median of US$59.50.
This is an external assessment, not a statement by Market Jury.
When does Beam Therapeutics report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 21% stronger than usual.
Does Beam Therapeutics pay a dividend?
Yes. The last dividend was US$0.23 per share, ex-date 04/11/2013, paid on 02/12/2013.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Beam Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Beam Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Beam Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.